STOCK TITAN

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) will release financial results for the three and 12 months ending December 31, 2023, followed by an investor conference call on March 26, 2024. Pre-registration for the call is available, with dial-in options for immediate access. The webcast will be accessible on the Company website, with a replay option.
Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Date/Time:

 

Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT

 

 

 

Pre-Registration:

 

Participants can pre-register for the conference call here:

 

 

 

 

 

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

 

 

 

Dial In:

 

Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:

 

833-816-1121 from within the U.S.

 

412-317-1862 from outside the U.S.

The live webcast of the conference call also will be available on the Events section of the Company website. A replay of the call will be available beginning two hours after its completion through April 16, 2024 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 1489846. The webcast will also be archived here.

About NovaBay Pharmaceuticals, Inc:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.com. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.

Socialize and Stay Informed on NovaBays Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com



Investor Contact

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Source: NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals will release its financial results on March 26, 2024.

The investor conference call will begin at 4:30 p.m. Eastern time on March 26, 2024.

Participants can pre-register for the conference call on the Company website.

The dial-in numbers are 833-816-1121 for U.S. callers and 412-317-1862 for international callers.

The replay of the conference call will be available until April 16, 2024.
NovaBay Pharmaceuticals, Inc.

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Stock Data

2.91M
29.93M
0.04%
3.95%
2.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About NBY

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across